The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in treating children and adolescents with chronic Hepatitis C infection, specifically genotypes 2 and 3. Hepatitis C is a liver infection caused by the Hepatitis C virus (HCV), and genotypes refer to the genetic variations of the virus. The study aims to determine if the investigational medication, given with another treatment, can effectively manage the condition in this age group.

Participants in the study will receive the investigational medication along with a second treatment for either 12 or 24 weeks. The study will monitor the safety of the treatment and how well it works in reducing the Hepatitis C virus in the body. Children and adolescents with genotypes 2 and 3 of the virus will be included to assess the treatment's impact on their health.

• Who can participate: This study is for children and adolescents with chronic Hepatitis C infection, specifically those with genotypes 2 and 3 of the virus.
• Study details: Participants will receive an investigational medication along with another treatment. The study will monitor the effects of the treatment on the Hepatitis C virus. A placebo, which is an inactive substance, will not be used in this study.